Advair Powder
Product Images NDC 50090-0731

Product Visual Gallery

This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Advair (NDC 50090-0731). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1. Cumulative Incidence Of Asthma-related Deaths In The 28-week Salmeterol Multi-center Asthma Research Trial (smart), By Duration Of Treatment (Advair Diskus Spl Graphic 01)

Chemical structure of fluticasone propionate, the active ingredient in ADVAIR DISKUS. The diagram shows the molecular arrangement including carbon, hydrogen, oxygen, sulfur, fluorine atoms, and the characteristic ring structures.*

FDA Label Image

Fluticasone Propionate Chemical Structure (Advair Diskus Spl Graphic 02)

Chemical structure diagram showing two molecular structures, representing the active ingredients fluticasone propionate and salmeterol found in ADVAIR DISKUS inhalation powder. The diagram includes various functional groups with hydroxyl and aromatic rings.*

FDA Label Image

Salmeterol Xinafoate Chemical Structure (Advair Diskus Spl Graphic 03)

This line graph compares percent change in FEV1 over 12 weeks among four groups: ADVAIR DISKUS 100/50 twice daily, fluticasone propionate 100 mcg twice daily, salmeterol 50 mcg twice daily, and placebo. The ADVAIR DISKUS group shows the highest improvement throughout the study period.*

FDA Label Image

Figure 2. Mean Percent Change From Baseline In Fev1 In Patients With Asthma Previously Treated With Either Inhaled Corticosteroids Or Salmeterol (study 1) (Advair Diskus Spl Graphic 04)

A line graph depicting the percentage change in FEV1 over 12 hours from baseline on Day 1 for four groups: ADVAIR DISKUS 100/50 twice daily, Salmeterol 50 mcg twice daily, Fluticasone propionate 100 mcg twice daily, and Placebo. The x-axis represents time in hours and the y-axis shows the percentage change in FEV1.*

FDA Label Image

Figure 3. Percent Change In Serial 12-hour Fev1 In Patients With Asthma Previously Using Either Inhaled Corticosteroids Or Salmeterol (study 1) (Advair Diskus Spl Graphic 05)

A line graph depicting the percentage change in FEV1 relative to day 1 baseline over a 12-hour period. The graph compares the effects of ADVAIR DISKUS 100/50 twice daily (N=73), salmeterol 50 mcg twice daily (N=49), fluticasone propionate 100 mcg twice daily (N=65), and placebo (N=26), with data points at multiple time intervals from day 1 baseline through week 12 baseline.*

FDA Label Image

Figure 4. Percent Change In Serial 12-hour Fev1 In Patients With Asthma Previously Using Either Inhaled Corticosteroids Or Salmeterol (study 1) (Advair Diskus Spl Graphic 06)

A line graph showing the percentage change in FEV1 over 24 weeks in three groups: ADVAIR DISKUS 250/50, Salmeterol 50 mcg, and placebo. The graph compares respiratory function improvement with time, including baseline FEV1 values and sample sizes at multiple time points.*

FDA Label Image

Figure 5 (Advair Diskus Spl Graphic 07)

Line graph showing the percent change in FEV1 (forced expiratory volume) over 24 weeks comparing ADVAIR DISKUS 250/50, fluticasone propionate 250 mcg, and placebo. The graph plots percentage change from day 1 to study endpoint with corresponding sample sizes at various weeks noted below.*

FDA Label Image

Figure 6 (Advair Diskus Spl Graphic 08)

An illustration of an ADVAIR DISKUS inhaler labeled with strength 100/50 micrograms. The diagram identifies parts of the inhaler including the outer case, mouthpiece, lever, thumb grip, and counter. The label on the device shows the proprietary name ADVAIR DISKUS and the active ingredients fluticasone propionate and salmeterol inhalation powder.*

FDA Label Image

Ifu Figure A (Advair Diskus Spl Graphic 09)

An instructional illustration showing a person holding an ADVAIR DISKUS inhaler with one hand and using the other hand to slide the inhaler lever to the right, demonstrating the mechanism to prepare the dose for inhalation.*

FDA Label Image

Ifu Figure B (Advair Diskus Spl Graphic 10)

An illustration showing a person's hand holding an ADVAIR DISKUS inhaler device in a position ready for use, demonstrating the hand placement for respiratory inhalation of the powdered medication.*

FDA Label Image

Ifu Figure C (Advair Diskus Spl Graphic 11)

Illustration showing a woman holding and using an ADVAIR DISKUS inhaler for respiratory powder inhalation. The image demonstrates the positioning of the device and inhalation technique for administering the medication.*

FDA Label Image

Ifu Figure D (Advair Diskus Spl Graphic 12)

An instructional illustration showing a woman using a purple, handheld inhalation device by placing it in her mouth and preparing to inhale the powder medication. The image highlights the proper technique for oral inhalation with a device similar to ADVAIR DISKUS.*

FDA Label Image

Ifu Figure E (Advair Diskus Spl Graphic 13)

An instructional illustration showing hands operating a purple ADVAIR DISKUS inhaler with an arrow indicating a sliding or twisting motion. The image demonstrates how to prepare the inhaler for use by moving a part of the device horizontally.*

FDA Label Image

Ifu Figure F (Advair Diskus Spl Graphic 14)

An instructional illustration showing a woman rinsing her mouth with water over a sink, with a glass of water placed nearby. The image suggests a step related to oral hygiene or medication aftercare, typically associated with inhalation treatments like ADVAIR DISKUS.*

FDA Label Image

Ifu Figure G (Advair Diskus Spl Graphic 15)

ADVAIR DISKUS 100/50 inhalation powder for respiratory use by A-S Medication Solutions shown as a purple, circular inhaler device. The label states 60 blisters containing fluticasone propionate and salmeterol, 100 mcg and 50 mcg strengths. The image highlights a blister marked with the number 5.*

FDA Label Image

Label Image (Lbl500900731)

Label for ADVAIR DISKUS inhalation powder containing fluticasone propionate and salmeterol. It includes dosage strengths, storage instructions to keep between 68 and 77 degrees Fahrenheit away from heat and sunlight, lot number, and barcode. Labeler is A-S Medication Solutions.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.